Skip to content

Strategy & Planning · Supply Chain · Warehousing & Transport

The Critical Role of Robust Logistics in Pharmaceutical Supply Chains

Rising Demand for Pharmaceutical Logistics Due to Aging Population Highlights Critical Importance of Medicine Supply Chains

Original source: Source information pending

The Critical Role of Robust Logistics in Pharmaceutical Supply Chains
📋 本文要点

Rising Demand for Pharmaceutical Logistics Due to Aging Population Highlights Critical Importance of Medicine Supply Chains

With the elderly becoming the fastest-growing demographic in Europe, increased healthcare needs are reshaping the pharmaceutical sector, emphasizing the need for robust and flexible logistics systems to keep up. This demand is driving the expansion of the European pharmaceutical market, which is expected to grow at an average annual rate of 5% by 2030. This growth is fueled by innovative therapies such as biologics and personalized medicine, which have more stringent transportation requirements. However, can road transport meet the demands for timely supply in today’s volatile and continuously disrupted logistics industry? And how should decarbonization issues within the supply chain be addressed?

The Importance of Compliance

With increasing demand for pharmaceuticals in Europe, efficient drug transportation has become crucial. Road freight accounts for 61% of cargo transport within the EU, making it essential to enhance road logistics for the pharmaceutical industry. As pharmaceutical products increasingly include highly sensitive items such as vaccines, biologics, and gene therapies, strict temperature control is critical. The Good Distribution Practice (GDP) guidelines, implemented in 2003 and updated in 2017, define standards for transporting medicines. Adhering to these standards is key and mandatory for logistics companies.

Maintaining Integrity Under Extreme Pressure

Pharmaceutical companies face significant challenges when transporting their sensitive products, especially under stringent requirements such as temperature control, regulatory compliance, and supply chain visibility. Additionally, it’s worth noting Europe’s efforts towards decarbonization. As pharmaceutical companies are pushing for decarbonization, they seek net-zero logistics solutions. Battery Electric Vehicles (BEV) and alternative fuels like HVO are initial solutions and transportation modes already operating within the pharmaceutical supply chain. The combination of these three solutions and future innovations can bring substantial emission reductions. For instance, combining HVO fuel and/or BEVs with multimodal transport can significantly reduce E2E emissions. With digital tools, results can be easily reported to companies as a presentation of Scope 3 emission reductions.

The Need for Digital Support and Opportunities

However, sustainable solutions are not the only requirement in pharmaceutical supply chains. Modern digital tools and new logistics equipment combined with round-the-clock monitoring make it easier to track shipments in real-time, control temperatures, and prevent delays. Using advanced tracking and monitoring systems, pharmaceutical companies can achieve the visibility and control needed to effectively follow and manage their supply chain, providing detailed information:

  • Temperature Stability: Ensuring that medicines, especially highly sensitive biologics, remain within required temperature ranges to maintain efficacy and safety.
  • Real-Time Visibility: Tracking goods throughout the transportation process to ensure no delays or interruptions endanger products. Immediate alerts can help address potential issues such as temperature deviations or delays.
  • Route Optimization: Automatically re-routing trucks to avoid delays caused by unforeseen events like border restrictions, local law enforcement actions, or sudden weather changes.

For example, when a shipment of critical vaccines faces potential delays due to border restrictions between France and Germany, the carrier automatically receives an alert and quickly defines new routes using digital tools—often leveraging robotic process automation or AI—to update expected arrival times and provide necessary information to all stakeholders.

“In an industry where time, compliance, and product integrity can save lives, choosing the right logistics partner is not just about operational efficiency—it’s about trust, reliability, and safeguarding global health. Years of experience remind us that every link and element in the supply chain matters; pharmaceutical companies are looking for those who understand high-risk logistics. The future of healthcare depends on this,” summarized Mark Mulder, Chief Commercial Officer at Girteka.


Source: Logistics Business

Ask SCI.AI Finished reading? Continue with SCI.AI. Explore the related policy, route, company and historical context. Continue asking
NRF: Early peak shipping season to subside in September
Supply Chain

NRF: Early peak shipping season to subside in September

The National Retail Federation (NRF) and Hackett Associates report that the early peak shipping season is ending, with U.S. port imports expected to decline for the rest of 2026. May was the busiest month at 2.24 million TEU. Tariff changes and supply chain disruptions drove retailers to pull forward orders. Consumer spending remains resilient. Full-year 2026 imports are projected at 25.5 million TEU, up 0.1% from 2025.

China’s exports rise 14%, imports up 22% amid trade war resilience
Supply Chain

China’s exports rise 14%, imports up 22% amid trade war resilience

China’s foreign trade rose 17.3% to ¥30.13 trillion in the first seven months of 2026, with exports up 14% and imports surging 22%. High-tech exports jumped over 50% in July, accounting for nearly 60% of monthly export growth. U.S.-China trade fell 1.6%, while ties with over 180 countries—including ASEAN and the EU—expanded. Green exports like EVs and lithium batteries posted double-digit growth for the 17th straight month. China also applies zero tariffs to imports from 63 countries.

TSMC revenue up 33.7%, ASML ships 86 lithography machines
Manufacturing

TSMC revenue up 33.7%, ASML ships 86 lithography machines

TSMC reported $40.2 billion in Q2 2026 revenue — up 33.7% year-on-year — with 2-nm process contributing 3% of sales. ASML shipped 86 new lithography machines in the same quarter, boosting revenue to €9.32 billion ($10.69 billion). TSMC holds 73% of the global foundry market, while ASML’s EUV tools remain essential for sub-3-nm chip production. Both companies’ five-year net income grew over 90% (ASML) and 251% (TSMC). TSMC’s $100 billion Arizona expansion will support 2-nm manufacturing and advanced packaging.

Welcome Back!

Login to your account below

Create New Account!

Fill the forms below to register

Retrieve your password

Please enter your username or email address to reset your password.

Scan to share via WeChat

Open WeChat and scan the QR code to share

QR Code

Add New Playlist